Dosimetric Validation of Scans Generated by GAN From Pre-therapeutic MRI in Stereotactic Cerebral Radiotherapy

Completed

• Conditions: Brain Metastases

• Registration Number: NCT04525053
• Lead Sponsor: University Hospital, Brest

Brief Summary

Stereotactic radiotherapy (SRT) is being widely accepted as a treatment of choice for patients with a small number of brain metastases and an acceptable size, allowing a better target dose conformity resulting in high local control rates and better sparing of organs at risk. Currently, imaging for such a delivery technique requires both a recent magnetic resonance imaging (MRI) brain study for volume definition and a computed tomography (CT) scan for SRT planning. An MRI-only workflow could reduce the risk of misalignment between the two imaging modalities and shorten the delay of planning. Given the absence of a calibrated electronic density on MRI, the investigators aim to assess the equivalence of synthetic CTs generated by a generative adversarial network (GAN) for planning in the brain SRT setting.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-16
• Status Verified: 2020-08
• Primary Completion: 2020-08-17
• Study Completion: 2020-08-17
• Study First Submitted: 2020-08-17
• Study First Submitted QC: 2020-08-20
• Last Update Submitted: 2020-08-20
• Study First Posted: 2020-08-25
• Last Update Posted: 2020-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 184

Inclusion Criteria

• age ≥ 18 years old
• SRT treatment for one or more brain metastasis(ses)
• brain MRI and planning CT scans realized less than 14 days prior to the treatment delivery

Exclusion Criteria

• MRI's field of view (FOV) judged insufficient for tumour(s) and OAR visualization

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Local Gamma Analysis Passing Rate	Once, at the time of treatment delivery	To be considered as comparable, 2 dose maps must have a Local Gamma Analysis Passing Rate higher than 98%. The primary outcome measure will be to compare the Local Gamma Analysis Passing Rate between the 2 dose maps (one initial dosimetric planification and one dosimetric planification extracted from the synthetic ct scan).

Secondary Outcome Measures

Name	Time	Method
Global Gamma Analysis Passing Rate	Once, at the time of treatment delivery	To be considered as comparable, 2 dose maps must have a Global Gamma Analysis Passing Rate higher than 95%. The primary outcome measure will be to compare the Global Gamma Analysis Passing Rate between the 2 dose maps (one initial dosimetric planification and one dosimetric planification extracted from the synthetic ct scan).
Planning Target Volume's coverage values	Once, at the time of treatment delivery	Planning Target Volume's (PTV) coverage values will be compared between the initial dosimetric planification and the dosimetric planification extracted from the synthetic ct scan.
Organs at risk Dose Constraints	Once, at the time of treatment delivery	Dose constraints to the Organs at Risks (OAR) will be compared between the initial dosimetric planification and the dosimetric planification extracted from the synthetic ct scan.

Trial Locations

Locations (1)

CHRU de Brest; 🇫🇷 Brest, France